CliffBio
small molecule

TEKTURNA

ALISKIREN HEMIFUMARATE

Loss of exclusivityAugust 2026latest FDA-listed patent expiry
CompanyLXO IRELAND DESIGNATED ACTIVITY CO

Drug detail

Brand nameTEKTURNA
Active ingredientALISKIREN HEMIFUMARATE
StrengthEQ 300MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2007
Marketing statusRX

Listed patents

PatentExpiresType
8617595*PEDAugust 2026—
8617595February 2026product

More from LXO IRELAND DESIGNATED ACTIVITY CO

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TEKTURNA patent cliff — loss of exclusivity August 2026 | CliffBio